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Background
Chronic rhinosinusitis with nasal polyps is hard to treat.
The therapeutic effect of doxycycline, oral glucocorti-
coids, mepolizumab and omalizumab with significant
reduction of nasal polyp score was previously investigated
by 3 randomized controlled trials. The aim of this study
is to compare the effect of these treatments on polyp
score, symptom scores and inflammatory parameters.
Methods
In total, 100 patients were randomly assigned to receive
doxycycline for 20 days (n=14), methylprednisolone in
decreasing doses for 20 days (n=14), mepolizumab 2 sin-
gle intravenous injections (n=20), omalizumab 2 to 4
subcutaneous doses (n=15) or placebo (n=37) in three
separate clinical double-blind, placebo-controlled trials.
Participants were followed for 8 weeks. Endoscopic eva-
luation of nasal polyp score, assessment of symptom
score and measurement of markers of inflammation in
nasal secretions and serum occurred at baseline, week 4
and week 8. All treatments were completed at week 4,
except for 2 patients who received a fourth subcuta-
neous dose of omalizumab at week 6.
Results
All treatment options significantly reduced nasal polyp
score as compared to baseline, but not placebo. Methyl-
prednisolone has initially the most dramatic effect on
symptom scores, but after cessation of treatment symp-
tom scores worsen progressively and return to baseline
after 4 weeks. Mepolizumab, doxycycline and methyl-
prednisolone each had a specific effect on local and sys-
temic inflammatory markers. Omalizumab did not alter
eosinophilia or markers of inflammation.
Conclusions
Omalizumab, mepolizumab and oral doxycycline cause a
long-term reduction in nasal polyp size, whereas methyl-
prednisolone initially causes the strongest reduction in
polyp size but recurrence occurs earlier. Total symptom
scores parallel this trend. Mepolizumab and doxycylin
work on eosinophilic and neutrophilic inflammtion in
nasal polyps, whereas the effect of methylprednisolone is
apparent on eosinophilic markers. Omalizumab did not
reduce markers of eosinophilic inflammation, nor neutro-
philic inflammation in nasal secretions. The beneficial
effect of omalizumab seems to be mediated through a
direct effect on IgE or their receptor, rather than through
an effect on markers of the eosinophilic cascade.
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